Asia FX cautious amid US govt shutdown; yen tumbles after Takaichi’s LDP win
SOUTH SAN FRANCISCO - Quince Therapeutics, Inc. (Nasdaq:QNCX) announced the publication of a population pharmacokinetic modeling study of its Phase 3 lead asset eDSP in the journal CPT: Pharmacometrics & Systems Pharmacology.
The study examined eDSP, a treatment that encapsulates dexamethasone sodium phosphate in a patient’s own red blood cells, in pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults. While the company is currently unprofitable, analysts tracked by InvestingPro maintain a strong buy consensus, with price targets significantly above current trading levels.
According to the published research, eDSP demonstrated sustained release properties, maintaining low plasma concentrations of the drug for 20 to 30 days without accumulation after monthly dosing. The two-compartment pharmacokinetic model showed that eDSP reaches peak levels within 0.67 hours post-infusion, followed by controlled release over several weeks.
The data supports eDSP’s potential to provide therapeutic benefits while reducing typical corticosteroid-related side effects. Previous clinical trials reported minimal adverse effects commonly associated with conventional corticosteroid use, such as adrenal suppression or cushingoid features, even after years of treatment.
A-T is a rare, inherited neurodegenerative disorder typically diagnosed before age five. The condition progressively worsens, often leading to wheelchair dependence by adolescence and a median lifespan of 25 to 30 years. According to company estimates, approximately 4,600 patients with A-T are diagnosed in the U.S. and about 5,000 in the U.K. and EU4 countries.
The eDSP treatment utilizes Quince’s proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which encapsulates medication in a patient’s own red blood cells to potentially improve drug tolerability and prolong circulation time.
The information in this article is based on a press release statement from Quince Therapeutics.
In other recent news, Quince Therapeutics has been the focus of several key developments. Citizens JMP recently lowered its price target for Quince Therapeutics to $8.00 from $9.00, maintaining a Market Outperform rating. The firm expressed confidence in the management’s execution of the pivotal NEAT trial for the treatment of Ataxia-Telangiectasia, citing the potential success of the high-dose eDSP treatment. Meanwhile, JMP Securities initiated coverage of Quince Therapeutics, assigning a Market Outperform rating with a price target of $9.00. This valuation is based on a risk-adjusted, discounted cash flow analysis of the company’s pipeline. Additionally, Quince Therapeutics announced the appointment of Dr. Hassan Abolhassani, an immunology expert, to its Scientific Advisory Board. Dr. Abolhassani’s expertise is expected to enhance the board’s focus on rare diseases. These recent developments reflect ongoing strategic efforts within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.